Antibiotic Development Needs Economic Incentives
The antibiotic market is categorically different from that of other pharmaceuticals. Research and development of any drug is expensive, but antibiotics have comparatively low prices and sales volume.
As a result, the companies making them are going bankrupt, and many potentially lifesaving drugs end up falling into an antibiotic valley of death—dropping out of production before they can reach patients.
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!